Aktis Oncology priced an upsized initial public offering and raised roughly $318 million, opening trading as one of the first biopharma IPOs of 2026. The company plans to fund phase 1b programs for two radioconjugates targeting Nectin‑4 and B7‑H3 and to advance companion imaging-based patient selection. The filings and market reception underline renewed investor appetite for platform radiopharmaceutical plays and miniprotein technology.